Promising Effect of Zolbetuximab and mFOLFOX6 Combination For Gastroesophageal Junction Adenocarcinoma

The SPOTLIGHT study, presented at ASCO GI, indicates promising effects of combining Zolbetuximab with mFOLFOX6 chemotherapy as first-line treatment for people with advanced gastroesophageal junction adenocarcinoma resistant to surgery. Kohei Shitara from the National Cancer Center Hospital East in Chiba, Japan, presents the results in this MEDtalk.